Phase I Clinical Trial of DA-6886 in Healthy Male Subjects

• Status: Completed
• Trial end date: 2014-04-01
• Target enrollment: 0
• Participant gender: Male

Summary

DA-6886_IBS_I is a phase I, dose block-randomized, double-blind, placebo-controlled, single/multiple dosing, dose escalation clinical trial with open-labelled food effect study of single dose to investigate the safety, tolerability and pharmacokinetics of DA-6886 after oral administration in healthy male subjects.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Dong-A Pharmaceutical Co., Ltd.; Dong-A ST Co., Ltd.

Criteria

Inclusion Criteria:

• 20 ~ 45 years old

• 27kg/m2 ≥ BMI ≥ 20kg/m2

• Healthy Male

• Informed consent

Exclusion Criteria:

• Clinically significant medical history

• smokers

• Clinically significant hypersensitivity of Drugs

• Clinically significant cutaneous disorder

• QTcB > 450msec

• have a history of drug abuse or show positive for drug abuse or cotinine at urine screening